M. Ramos

Preventive treatments for breast cancer: recent developments

A. Ruíz, R. Andrés, A. Barnadas, 2014, Clinical and Translational Oncology.

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).

F. Rojo, J. Albanell, M. Margelí, 2021, European journal of cancer.

Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia

X. Badia, M. Pastor, M. Margelí, 2007 .

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

S. González, M. Margelí, E. Carrasco, 2019, Journal of Patient-Reported Outcomes.

Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors (GF) to TAC. GE

A. Lluch, M. Martín, M. Ramos, 2005 .